<p>Stance Capital LLC 在第二季度收购了 Gilead Sciences, Inc.（NASDAQ:GILD - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的文件。该基金收购了 11,825 股生物制药公司的股票，价值约为 1,311,000 美元。</p>
<ul>
<li>3 家将大现金流转化为更大股东收益的公司</li>
</ul>
<p>其他对冲基金最近也增加或减少了在该公司的股份。GoalVest Advisory LLC 在第二季度将其在 Gilead Sciences 的股份增加了 7,566.7%。GoalVest Advisory LLC 目前拥有 230 股生物制药公司的股票，价值 26,000 美元，此前在此期间又收购了 227 股。Activest Wealth Management 在第一季度将其在 Gilead Sciences 的股份增加了 2,837.5%。Activest Wealth Management 目前拥有 235 股生物制药公司的股票，价值 26,000 美元，此前在此期间又收购了 227 股。Harbor Asset Planning Inc. 在第二季度收购了 Gilead Sciences 的新股份，价值约为 27,000 美元。Howard Hughes Medical Institute 在第二季度收购了 Gilead Sciences 的新头寸，价值 30,000 美元。最后，Putney Financial Group LLC 在第二季度将其在 Gilead Sciences 的持股增加了 53.4%。Putney Financial Group LLC 目前拥有 270 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 94 股。机构投资者持有该公司 83.67% 的股份。</p>
<p>获取 <strong>Gilead Sciences</strong> 警报：</p>
<h2>Gilead Sciences 价格表现</h2>
<p>GILD 的股票在周五开盘价为 120.40 美元。该股票的 50 日简单移动平均线为 121.89 美元，200 日简单移动平均线为 115.76 美元。Gilead Sciences, Inc. 的 52 周低点为 88.57 美元，52 周高点为 128.70 美元。该公司的债务与股本比率为 1.03，速动比率为 1.31，流动比率为 1.45。该公司的市值为 1493.8 亿美元，市盈率为 18.67，市盈增长比率为 0.67，贝塔系数为 0.32。</p>
<ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>Gilead Sciences（NASDAQ:GILD - 获取免费报告）最近于 10 月 30 日（星期四）公布了季度财报。该生物制药公司报告本季度每股收益为 2.47 美元，超出分析师一致预期的 2.16 美元，超出幅度为 0.31 美元。该公司本季度的收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。Gilead Sciences 的净利润率为 27.88%，股本回报率为 51.86%。该公司的收入同比增长 3.0%。在去年同期，该公司每股收益为 2.02 美元。Gilead Sciences 已将其 2025 财年的指引设定为每股收益 8.050-8.250。卖方分析师预测 Gilead Sciences, Inc. 本财年将发布 7.95 的每股收益。</p>
<h2>Gilead Sciences 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记在册的股东将获得 0.79 美元的分红。该分红的除息日为 12 月 15 日（星期一）。这代表着年化分红为 3.16 美元，分红收益率为 2.6%。Gilead Sciences 的分红支付比率（DPR）目前为 48.99%。</p>
<h2>内部买卖</h2>
<ul>
<li>3 家现金充裕且具有高增长潜力的股票</li>
</ul>
<p>在其他消息中，董事 Jeffrey Bluestone 于 11 月 28 日（星期五）出售了 5,000 股该公司的股票，交易发生在平均价格为 125.08 美元，总交易额为 625,400.00 美元。交易完成后，该董事直接持有 8,920 股公司股票，价值 1,115,713.60 美元。这笔交易代表其持股减少了 35.92%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。此外，内部人士 Johanna Mercier 于 11 月 17 日（星期一）出售了 28,000 股公司的股票，交易发生在平均价格为 125.86 美元，总交易额为 3,524,080.00 美元。交易完成后，该内部人士直接持有 107,193 股公司股票，价值约为 13,491,310.98 美元。这代表其持股减少了 20.71%。该出售的披露在 SEC 文件中可获得。在上个季度，内部人士出售了 135,757 股公司股票，价值 16,616,127 美元。公司内部人士持有该公司 0.27% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司对 GILD 发表了评论。富国银行将 Gilead Sciences 的目标价从 145.00 美元上调至 150.00 美元，并在周三的研究报告中给予该股票 “超配” 评级。BMO Capital Markets 在 11 月 25 日（星期二）的研究报告中对 Gilead Sciences 的股票设定了 135.00 美元的目标价。Cantor Fitzgerald 在 10 月 31 日（星期五）的研究报告中重申了 “超配” 评级，并设定了 135.00 美元的目标价。大和美国在 8 月 19 日（星期二）的报告中将 Gilead Sciences 的股票评级从 “持有” 上调至 “强力买入”。最后，花旗集团在 10 月 8 日（星期三）的报告中将 Gilead Sciences 的目标价从 125.00 美元上调至 135.00 美元，并给予该股票 “买入” 评级。两位研究分析师对该股票给予强力买入评级，22 位给予买入评级，4 位给予持有评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价为 131.13 美元。</p>
<p><strong>查看我们关于 GILD 的最新报告</strong></p>
<h2>关于 Gilead Sciences</h2>
<p>（免费报告）</p>
<p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种静脉注射药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比吉利德科学更好</li>
<li>股票中的缺口上涨意味着什么？如何利用缺口</li>
<li>迪士尼与 OpenAI 达成 10 亿美元交易，带来魔力</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>什么是股息挑战者？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><strong>想看看其他对 GILD 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com，获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
<p>在你考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

<p>Stance Capital LLC 在第二季度收购了 11,825 股吉利德科学（Gilead Sciences, Inc.，NASDAQ:GILD），价值约为 1,311,000 美元。其他对冲基金也增加了在吉利德科学的持仓。该公司的股票在周五开盘价为 120.40 美元，52 周范围为 88.57 美元至 128.70 美元。吉利德科学报告的季度每股收益为 2.47 美元，超出预期，并宣布季度股息为每股 0.79 美元。内部人士在上个季度出售了 135,757 股，价值 16,616,127 美元。分析师预测吉利德科学将实现增长</p>

<p>Stance Capital LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,825 shares of the biopharmaceutical company's stock, valued at approximately $1,311,000.</p>
<div class="lb-trans"><p>Stance Capital LLC 在第二季度收购了 Gilead Sciences, Inc.（NASDAQ:GILD - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的文件。该基金收购了 11,825 股生物制药公司的股票，价值约为 1,311,000 美元。</p>
</div><ul>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家将大现金流转化为更大股东收益的公司</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the period. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the second quarter valued at approximately $27,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth $30,000. Finally, Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金最近也增加或减少了在该公司的股份。GoalVest Advisory LLC 在第二季度将其在 Gilead Sciences 的股份增加了 7,566.7%。GoalVest Advisory LLC 目前拥有 230 股生物制药公司的股票，价值 26,000 美元，此前在此期间又收购了 227 股。Activest Wealth Management 在第一季度将其在 Gilead Sciences 的股份增加了 2,837.5%。Activest Wealth Management 目前拥有 235 股生物制药公司的股票，价值 26,000 美元，此前在此期间又收购了 227 股。Harbor Asset Planning Inc. 在第二季度收购了 Gilead Sciences 的新股份，价值约为 27,000 美元。Howard Hughes Medical Institute 在第二季度收购了 Gilead Sciences 的新头寸，价值 30,000 美元。最后，Putney Financial Group LLC 在第二季度将其在 Gilead Sciences 的持股增加了 53.4%。Putney Financial Group LLC 目前拥有 270 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 94 股。机构投资者持有该公司 83.67% 的股份。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gilead Sciences</strong> 警报：</p>
</div><h2>Gilead Sciences Price Performance</h2>
<div class="lb-trans"><h2>Gilead Sciences 价格表现</h2>
</div><p>Shares of GILD opened at $120.40 on Friday. The stock has a 50 day simple moving average of $121.89 and a 200 day simple moving average of $115.76. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a market capitalization of $149.38 billion, a PE ratio of 18.67, a P/E/G ratio of 0.67 and a beta of 0.32.</p>
<div class="lb-trans"><p>GILD 的股票在周五开盘价为 120.40 美元。该股票的 50 日简单移动平均线为 121.89 美元，200 日简单移动平均线为 115.76 美元。Gilead Sciences, Inc. 的 52 周低点为 88.57 美元，52 周高点为 128.70 美元。该公司的债务与股本比率为 1.03，速动比率为 1.31，流动比率为 1.45。该公司的市值为 1493.8 亿美元，市盈率为 18.67，市盈增长比率为 0.67，贝塔系数为 0.32。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts' consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business's revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Gilead Sciences（NASDAQ:GILD - 获取免费报告）最近于 10 月 30 日（星期四）公布了季度财报。该生物制药公司报告本季度每股收益为 2.47 美元，超出分析师一致预期的 2.16 美元，超出幅度为 0.31 美元。该公司本季度的收入为 77.7 亿美元，而分析师预期为 74.2 亿美元。Gilead Sciences 的净利润率为 27.88%，股本回报率为 51.86%。该公司的收入同比增长 3.0%。在去年同期，该公司每股收益为 2.02 美元。Gilead Sciences 已将其 2025 财年的指引设定为每股收益 8.050-8.250。卖方分析师预测 Gilead Sciences, Inc. 本财年将发布 7.95 的每股收益。</p>
</div><h2>Gilead Sciences Announces Dividend</h2>
<div class="lb-trans"><h2>Gilead Sciences 宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences's dividend payout ratio (DPR) is currently 48.99%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 12 月 30 日（星期二）支付。12 月 15 日（星期一）登记在册的股东将获得 0.79 美元的分红。该分红的除息日为 12 月 15 日（星期一）。这代表着年化分红为 3.16 美元，分红收益率为 2.6%。Gilead Sciences 的分红支付比率（DPR）目前为 48.99%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家现金充裕且具有高增长潜力的股票</li>
</ul>
</div><p>In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 135,757 shares of company stock valued at $16,616,127. Corporate insiders own 0.27% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事 Jeffrey Bluestone 于 11 月 28 日（星期五）出售了 5,000 股该公司的股票，交易发生在平均价格为 125.08 美元，总交易额为 625,400.00 美元。交易完成后，该董事直接持有 8,920 股公司股票，价值 1,115,713.60 美元。这笔交易代表其持股减少了 35.92%。该出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。此外，内部人士 Johanna Mercier 于 11 月 17 日（星期一）出售了 28,000 股公司的股票，交易发生在平均价格为 125.86 美元，总交易额为 3,524,080.00 美元。交易完成后，该内部人士直接持有 107,193 股公司股票，价值约为 13,491,310.98 美元。这代表其持股减少了 20.71%。该出售的披露在 SEC 文件中可获得。在上个季度，内部人士出售了 135,757 股公司股票，价值 16,616,127 美元。公司内部人士持有该公司 0.27% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have commented on GILD. Wells Fargo &amp; Company boosted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday. BMO Capital Markets set a $135.00 target price on shares of Gilead Sciences in a research report on Tuesday, November 25th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Daiwa America upgraded shares of Gilead Sciences from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Tuesday, August 19th. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $131.13.</p>
<div class="lb-trans"><p>多家研究公司对 GILD 发表了评论。富国银行将 Gilead Sciences 的目标价从 145.00 美元上调至 150.00 美元，并在周三的研究报告中给予该股票 “超配” 评级。BMO Capital Markets 在 11 月 25 日（星期二）的研究报告中对 Gilead Sciences 的股票设定了 135.00 美元的目标价。Cantor Fitzgerald 在 10 月 31 日（星期五）的研究报告中重申了 “超配” 评级，并设定了 135.00 美元的目标价。大和美国在 8 月 19 日（星期二）的报告中将 Gilead Sciences 的股票评级从 “持有” 上调至 “强力买入”。最后，花旗集团在 10 月 8 日（星期三）的报告中将 Gilead Sciences 的目标价从 125.00 美元上调至 135.00 美元，并给予该股票 “买入” 评级。两位研究分析师对该股票给予强力买入评级，22 位给予买入评级，4 位给予持有评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价为 131.13 美元。</p>
</div><p><strong>Check Out Our Latest Report on GILD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GILD 的最新报告</strong></p>
</div><h2>About Gilead Sciences</h2>
<div class="lb-trans"><h2>关于 Gilead Sciences</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种静脉注射药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>What Are Dividend Challengers?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比吉利德科学更好</li>
<li>股票中的缺口上涨意味着什么？如何利用缺口</li>
<li>迪士尼与 OpenAI 达成 10 亿美元交易，带来魔力</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>什么是股息挑战者？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GILD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 GILD 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com，获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stance Capital LLC 在吉利德科学公司（Gilead Sciences, Inc.）的股票代码 $GILD 中建立了头寸